Literature DB >> 35661912

Negative symptoms are associated with modularity and thalamic connectivity in schizophrenia.

Adem Bayrakçı1, Nabi Zorlu2, Merve Karakılıç1, Funda Gülyüksel1, Berna Yalınçetin3, Elif Oral1, Fazıl Gelal4, Emre Bora3,5,6.   

Abstract

Negative symptoms, including avolition, anhedonia, asociality, blunted affect and alogia are associated with poor long-term outcome and functioning. However, treatment options for negative symptoms are limited and neurobiological mechanisms underlying negative symptoms in schizophrenia are still poorly understood. Diffusion-weighted magnetic resonance imaging scans were acquired from 64 patients diagnosed with schizophrenia and 35 controls. Global and regional network properties and rich club organization were investigated using graph analytical methods. We found that the schizophrenia group had higher modularity, clustering coefficient and characteristic path length, and lower rich connections compared to controls, suggesting highly connected nodes within modules but less integrated with nodes in other modules in schizophrenia. We also found a lower nodal degree in the left thalamus and left putamen in schizophrenia relative to the control group. Importantly, higher modularity was associated with greater negative symptoms but not with cognitive deficits in patients diagnosed with schizophrenia suggesting an alteration in modularity might be specific to overall negative symptoms. The nodal degree of the left thalamus was associated with both negative and cognitive symptoms. Our findings are important for improving our understanding of abnormal white-matter network topology underlying negative symptoms in schizophrenia.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany.

Entities:  

Keywords:  DTI; Modularity; Negative symptoms; Schizophrenia; Thalamus

Year:  2022        PMID: 35661912     DOI: 10.1007/s00406-022-01433-5

Source DB:  PubMed          Journal:  Eur Arch Psychiatry Clin Neurosci        ISSN: 0940-1334            Impact factor:   5.270


  81 in total

1.  Electron microscopy of oligodendroglia in severe mental illness.

Authors:  N Uranova; D Orlovskaya; O Vikhreva; I Zimina; N Kolomeets; V Vostrikov; V Rachmanova
Journal:  Brain Res Bull       Date:  2001-07-15       Impact factor: 4.077

2.  Negative symptoms have greater impact on functioning than positive symptoms in schizophrenia: analysis of CATIE data.

Authors:  Jonathan Rabinowitz; Stephen Z Levine; George Garibaldi; Dragana Bugarski-Kirola; Carmen Galani Berardo; Shitij Kapur
Journal:  Schizophr Res       Date:  2012-02-06       Impact factor: 4.939

Review 3.  Management of negative symptoms of schizophrenia.

Authors:  D C Javitt
Journal:  Curr Psychiatry Rep       Date:  2001-10       Impact factor: 5.285

4.  Social competence versus negative symptoms as predictors of real world social functioning in schizophrenia.

Authors:  Belinda R Robertson; Davide Prestia; Elizabeth W Twamley; Thomas L Patterson; Christopher R Bowie; Philip D Harvey
Journal:  Schizophr Res       Date:  2014-11-07       Impact factor: 4.939

Review 5.  A separate disease within the syndrome of schizophrenia.

Authors:  B Kirkpatrick; R W Buchanan; D E Ross; W T Carpenter
Journal:  Arch Gen Psychiatry       Date:  2001-02

6.  Categorical and dimensional approaches to negative symptoms of schizophrenia: focus on long-term stability and functional outcome.

Authors:  Silvana Galderisi; Paola Bucci; Armida Mucci; Brian Kirkpatrick; Stefano Pini; Alessandro Rossi; Antonio Vita; Mario Maj
Journal:  Schizophr Res       Date:  2013-04-19       Impact factor: 4.939

Review 7.  Pathophysiology of negative symptom dimensions of schizophrenia - Current developments and implications for treatment.

Authors:  Indrit Bègue; Stefan Kaiser; Matthias Kirschner
Journal:  Neurosci Biobehav Rev       Date:  2020-06-10       Impact factor: 8.989

8.  Oligodendroglial density in the prefrontal cortex in schizophrenia and mood disorders: a study from the Stanley Neuropathology Consortium.

Authors:  Natalya A Uranova; Victor M Vostrikov; Diana D Orlovskaya; Valentina I Rachmanova
Journal:  Schizophr Res       Date:  2004-04-01       Impact factor: 4.939

9.  Treatments of Negative Symptoms in Schizophrenia: Meta-Analysis of 168 Randomized Placebo-Controlled Trials.

Authors:  Paolo Fusar-Poli; Evangelos Papanastasiou; Daniel Stahl; Matteo Rocchetti; William Carpenter; Sukhwinder Shergill; Philip McGuire
Journal:  Schizophr Bull       Date:  2014-12-20       Impact factor: 9.306

10.  Widespread white matter microstructural differences in schizophrenia across 4322 individuals: results from the ENIGMA Schizophrenia DTI Working Group.

Authors:  S Kelly; N Jahanshad; A Zalesky; P Kochunov; I Agartz; C Alloza; O A Andreassen; C Arango; N Banaj; S Bouix; C A Bousman; R M Brouwer; J Bruggemann; J Bustillo; W Cahn; V Calhoun; D Cannon; V Carr; S Catts; J Chen; J-X Chen; X Chen; C Chiapponi; Kl K Cho; V Ciullo; A S Corvin; B Crespo-Facorro; V Cropley; P De Rossi; C M Diaz-Caneja; E W Dickie; S Ehrlich; F-M Fan; J Faskowitz; H Fatouros-Bergman; L Flyckt; J M Ford; J-P Fouche; M Fukunaga; M Gill; D C Glahn; R Gollub; E D Goudzwaard; H Guo; R E Gur; R C Gur; T P Gurholt; R Hashimoto; S N Hatton; F A Henskens; D P Hibar; I B Hickie; L E Hong; J Horacek; F M Howells; H E Hulshoff Pol; C L Hyde; D Isaev; A Jablensky; P R Jansen; J Janssen; E G Jönsson; L A Jung; R S Kahn; Z Kikinis; K Liu; P Klauser; C Knöchel; M Kubicki; J Lagopoulos; C Langen; S Lawrie; R K Lenroot; K O Lim; C Lopez-Jaramillo; A Lyall; V Magnotta; R C W Mandl; D H Mathalon; R W McCarley; S McCarthy-Jones; C McDonald; S McEwen; A McIntosh; T Melicher; R I Mesholam-Gately; P T Michie; B Mowry; B A Mueller; D T Newell; P O'Donnell; V Oertel-Knöchel; L Oestreich; S A Paciga; C Pantelis; O Pasternak; G Pearlson; G R Pellicano; A Pereira; J Pineda Zapata; F Piras; S G Potkin; A Preda; P E Rasser; D R Roalf; R Roiz; A Roos; D Rotenberg; T D Satterthwaite; P Savadjiev; U Schall; R J Scott; M L Seal; L J Seidman; C Shannon Weickert; C D Whelan; M E Shenton; J S Kwon; G Spalletta; F Spaniel; E Sprooten; M Stäblein; D J Stein; S Sundram; Y Tan; S Tan; S Tang; H S Temmingh; L T Westlye; S Tønnesen; D Tordesillas-Gutierrez; N T Doan; J Vaidya; N E M van Haren; C D Vargas; D Vecchio; D Velakoulis; A Voineskos; J Q Voyvodic; Z Wang; P Wan; D Wei; T W Weickert; H Whalley; T White; T J Whitford; J D Wojcik; H Xiang; Z Xie; H Yamamori; F Yang; N Yao; G Zhang; J Zhao; T G M van Erp; J Turner; P M Thompson; G Donohoe
Journal:  Mol Psychiatry       Date:  2017-10-17       Impact factor: 15.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.